Physician Perspectives 2017: Ustekinumab in IBD Therapeutics Poses Superlative Outcome over Anti-TNF Therapy
Inflammatory bowel disease (IBD) is an acute digestive disorder characterized by severe digestive tract inflammation. Increased occurrences of IBD maladies such as Crohn's disease has instigated massive research initiatives in therapeutics development of IBD. Significant advances towards development of alternative therapeutics such as ustekinumab as a potential substitute for prevalent therapeutics such as anti-TNF therapy is likely to direct new growth roadmap for ustekinumab in IBD therapeutics.
View full press release